Simon Blanc

Background Clinical trials have demonstrated improved disease-free survival and overall survival in HER2-negative early-stage breast cancer patients with germline BRCA1/2 mutations who received adjuvant PARP inhibitors. It remains critical to assess BRCA1/2 testing patterns in clinical care to ensure that patients have access to all treatment options.

Systemic mastocytosis (SM) is a clonal mast cell neoplasm that is driven by KIT D816V mutation in ∼95% of adults with SM. Indolent systemic mastocytosis (ISM) is a mast cell disease characterized by debilitating neurologic, musculoskeletal, gastrointestinal, and cutaneous symptoms and poor quality of life (QoL). The objective of this study was to characterize the symptom burden of patients with ISM.